JMP Securities Maintains Adicet Bio(ACET.US) With Hold Rating

Moomoo NewsFeb 6 01:31 ET · Ratings

Cautious Neutral Recommendation on Adicet Bio Amidst Uncertain Clinical Outcomes and Fair Valuation

TipRanksFeb 6 00:45 ET

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) With Extrarenal Involvement

BusinesswireFeb 5 07:10 ET

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

BusinesswireJan 29 07:00 ET

Adicet Bio Highlights Key 2025 Milestones Following 2024 Progress

BenzingaJan 8 16:13 ET

Express News | Adicet Bio Inc - Preliminary Data for Adi-001 in Ln Expected in 1H25

ReutersJan 8 16:11 ET